CABANA trial: “beauty is in the eye of the beholder”

David Briceno, Prasant Mohanty, Luigi Di Biase, Jorge E. Romero, Domenico Giovanni Della Rocca, Chintan Trivedi, Sanghamitra Mohanty, Andrea Natale

Research output: Contribution to journalComment/debate

Abstract

The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.

Original languageEnglish (US)
JournalJournal of Interventional Cardiac Electrophysiology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Beauty
Catheter Ablation
Atrial Fibrillation
Heart Arrest
Stroke
Quality of Life
Hemorrhage
Drug Therapy

Keywords

  • Ablation
  • Atrila fibrillation
  • Mortality
  • Outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

CABANA trial : “beauty is in the eye of the beholder”. / Briceno, David; Mohanty, Prasant; Di Biase, Luigi; Romero, Jorge E.; Rocca, Domenico Giovanni Della; Trivedi, Chintan; Mohanty, Sanghamitra; Natale, Andrea.

In: Journal of Interventional Cardiac Electrophysiology, 01.01.2019.

Research output: Contribution to journalComment/debate

Briceno, David ; Mohanty, Prasant ; Di Biase, Luigi ; Romero, Jorge E. ; Rocca, Domenico Giovanni Della ; Trivedi, Chintan ; Mohanty, Sanghamitra ; Natale, Andrea. / CABANA trial : “beauty is in the eye of the beholder”. In: Journal of Interventional Cardiac Electrophysiology. 2019.
@article{ea202f9f3eb04ce8a042835d413a899c,
title = "CABANA trial: “beauty is in the eye of the beholder”",
abstract = "The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.",
keywords = "Ablation, Atrila fibrillation, Mortality, Outcomes",
author = "David Briceno and Prasant Mohanty and {Di Biase}, Luigi and Romero, {Jorge E.} and Rocca, {Domenico Giovanni Della} and Chintan Trivedi and Sanghamitra Mohanty and Andrea Natale",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10840-019-00604-0",
language = "English (US)",
journal = "Journal of Interventional Cardiac Electrophysiology",
issn = "1383-875X",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - CABANA trial

T2 - “beauty is in the eye of the beholder”

AU - Briceno, David

AU - Mohanty, Prasant

AU - Di Biase, Luigi

AU - Romero, Jorge E.

AU - Rocca, Domenico Giovanni Della

AU - Trivedi, Chintan

AU - Mohanty, Sanghamitra

AU - Natale, Andrea

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.

AB - The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.

KW - Ablation

KW - Atrila fibrillation

KW - Mortality

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=85071752613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071752613&partnerID=8YFLogxK

U2 - 10.1007/s10840-019-00604-0

DO - 10.1007/s10840-019-00604-0

M3 - Comment/debate

AN - SCOPUS:85071752613

JO - Journal of Interventional Cardiac Electrophysiology

JF - Journal of Interventional Cardiac Electrophysiology

SN - 1383-875X

ER -